BCR and chronic myelogenous leukemia, BCR-ABL1 positive: As shown in Figure 1C, in contrast to imatinib inhibiting p-BCR-ABL Y177 only in imatinib sensitive cells, SPO dephosphorylated BCR-ABL Y177 in all cell lines, including the CML cells bearing T315I mutation.